Your session is about to expire
← Back to Search
Other
Single Dose for Mass Balance Recovery
Phase 1
Waitlist Available
Research Sponsored by InventisBio Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Healthy adult female volunteers not of child-bearing potential between the ages of 18 and 65. Other inclusion criteria will be reviewed by the Principal Investigator.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights
Study Summary
This trial is to test a new drug in healthy women and study how it is metabolized and excreted.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Radiolabel recovery
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single DoseExperimental Treatment1 Intervention
All study subjects will receive a a single oral dose of radiolabeled microtracer of D-0502 following an overnight fast
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[14C]-D-0502
2022
Completed Phase 1
~10
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
InventisBio Co., LtdLead Sponsor
19 Previous Clinical Trials
1,951 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger